



[REDACTED]

23 June 2021

Dear [REDACTED]

**Freedom of Information request: FOI2021/00288**

Thank you for your Freedom of Information request received on the 10 June in which you requested the following:

**Your request:**

*RE: FOI2021/00242: Freedom of Information request response*

*1. The Ivermectin meta-analysis reviewed at the meeting concludes that "This meta-analysis of 18 RCTs in 2282 patients showed a 75% improvement in survival, faster time to clinical recovery and signs of a dose-dependent effect of viral clearance for patients given ivermectin versus control treatment." And that "the current paucity of high-quality evidence only highlights the clear need for additional, higher-quality and larger-scale clinical trials, warranted to investigate the use of ivermectin further". I would like to know in what ways this meta-analysis "supported the panels original recommendation not to prioritise Ivermectin"?*

*2. The Merck statement on Ivermectin noted at UK-CTAP 10/02/2021 does not contain or cite any research about the efficacy of ivermectin for treatment of covid-19. Why was this statement reviewed at the meeting, who tabled this statement for consideration at the meeting, and what weight was given to this statement in the decisions made at that meeting?*

**Our response**

I can confirm UK Research and Innovation (UKRI) do not hold the information relevant to your request.

Following a search of our records we can confirm that UKRI do not hold recorded information relevant to your request. Additionally, your questions do not fall within the scope of FOIA as we are unable to provide comment, explanations or opinions. Specifically, with regard to part 1 of your request, the meta-analysis was not reviewed in isolation, but rather as part of a wider body of evidence and to make a comment on the role of a single meta-analysis would not reflect the deliberation of the panel. On part 2, the Merck statement was introduced as part of the emerging evidence base, as outlined in our earlier response (FOI2021/00242).

Please note that we only record decisions and not full minutes for the UK-CTAP meetings. We therefore do not hold any further records relevant to the request, as the information previously provided to you is all information we hold of relevance to the decisions regarding Ivermectin.

If you have any queries regarding our response or you are unhappy with the outcome of your request and wish to seek an internal review of the decision, please contact:

Head of Information Governance


Email: [foi@ukri.org](mailto:foi@ukri.org) or [infogovernance@ukri.org](mailto:infogovernance@ukri.org)

Please quote the reference number above in any future communications.

If you are still not content with the outcome of the internal review, you may apply to refer the matter to the Information Commissioner for a decision. Generally, the ICO cannot make a decision unless you have exhausted the review procedure provided by UKRI. The Information Commissioner can be contacted at: <http://www.ico.gov.uk/>

If you wish to raise a complaint regarding the service you have received or the conduct of any UKRI staff in relation to your request, please see UKRI's complaints policy: <https://www.ukri.org/about-us/policies-and-standards/complaints-policy/>

Yours sincerely,

  
Information Governance  
Information Rights Team  
UK Research and Innovation  
[foi@ukri.org](mailto:foi@ukri.org) | [dataprotection@ukri.org](mailto:dataprotection@ukri.org)